Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1991 Nov;35(11):2329–2334. doi: 10.1128/aac.35.11.2329

In vitro studies with five quinolones: evidence for changes in relative potency as quinolone resistance rises.

K S Thomson 1, C C Sanders 1, M E Hayden 1
PMCID: PMC245380  PMID: 1804005

Abstract

A panel of 203 staphylococci, Enterobacteriaceae, Pseudomonas aeruginosa, and miscellaneous nonfermentative gram-negative bacilli were chosen for their various susceptibilities to ciprofloxacin. On the basis of agar dilution susceptibilities, each of the four taxonomic groups was divided into ciprofloxacin-susceptible, moderately resistant, and highly resistant subgroups, and each subgroup was then further analyzed for its susceptibility to the fluoroquinolones CI-960, CI-990, sparfloxacin, and ofloxacin. Although the MICs of each quinolone increased as ciprofloxacin resistance increased, the potency of CI-960 appeared to increase relative to the potencies of the other quinolones. Similarly, the MICs of sparfloxacin and ofloxacin appeared to be less affected by ciprofloxacin resistance than were the MICs of ciprofloxacin or CI-990. Single-step mutants of representative clinical isolates with different levels of ciprofloxacin resistance were selected to determine whether the study quinolones differed in their propensity to select resistant mutants and whether the presence of preexisting ciprofloxacin resistance influenced the subsequent development of resistance. Each of the five fluoroquinolones and nalidixic acid selected mutants that exhibited generally modest decreases in quinolone susceptibility (4- to 16-fold). However, CI-960 inhibited significantly more mutants (80%) than did the other quinolones (39 to 59%) at a concentration of 1 microgram/ml. The presence of preexisting ciprofloxacin resistance appeared to be associated with higher mutational frequencies in coagulase-negative staphylococci exposed to each of the fluoroquinolones and in Serratia marcescens exposed to nalidixic acid. Preexisting ciprofloxacin resistance did not influence the development of resistance in the strains of Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, or Pseudomonas aeruginosa that were studied. The results of this study suggest that quinolones are not affected equally by all resistance mechanisms, and although each one can select mutants, some quinolones may be active against these mutants at clinically achievable concentrations.

Full text

PDF
2329

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Acar J. F., Francoual S. The clinical problems of bacterial resistance to the new quinolones. J Antimicrob Chemother. 1990 Oct;26 (Suppl B):207–213. doi: 10.1093/jac/26.suppl_b.207. [DOI] [PubMed] [Google Scholar]
  2. Cohen S. P., McMurry L. M., Hooper D. C., Wolfson J. S., Levy S. B. Cross-resistance to fluoroquinolones in multiple-antibiotic-resistant (Mar) Escherichia coli selected by tetracycline or chloramphenicol: decreased drug accumulation associated with membrane changes in addition to OmpF reduction. Antimicrob Agents Chemother. 1989 Aug;33(8):1318–1325. doi: 10.1128/aac.33.8.1318. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Hooper D. C., Wolfson J. S. Bacterial resistance to the quinolone antimicrobial agents. Am J Med. 1989 Dec 29;87(6C):17S–23S. [PubMed] [Google Scholar]
  4. Jonsson M., Walder M., Forsgren A. First clinical isolate of highly fluoroquinolone-resistant Escherichia coli in Scandanavia. Eur J Clin Microbiol Infect Dis. 1990 Nov;9(11):851–853. doi: 10.1007/BF01967392. [DOI] [PubMed] [Google Scholar]
  5. Maple P. A., Hamilton-Miller J. M., Brumfitt W. Differing activities of quinolones against ciprofloxacin-susceptible and ciprofloxacin-resistant, methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 1991 Feb;35(2):345–350. doi: 10.1128/aac.35.2.345. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Masecar B. L., Robillard N. J. Spontaneous quinolone resistance in Serratia marcescens due to a mutation in gyrA. Antimicrob Agents Chemother. 1991 May;35(5):898–902. doi: 10.1128/aac.35.5.898. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Muder R. R., Brennen C., Goetz A. M., Wagener M. M., Rihs J. D. Association with prior fluoroquinolone therapy of widespread ciprofloxacin resistance among gram-negative isolates in a Veterans Affairs medical center. Antimicrob Agents Chemother. 1991 Feb;35(2):256–258. doi: 10.1128/aac.35.2.256. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Pace J., Bertasso A., Georgopapadakou N. H. Escherichia coli resistant to cephalosporins and quinolones is still susceptible to the cephalosporin-quinolone ester Ro 23-9424. Antimicrob Agents Chemother. 1991 May;35(5):910–915. doi: 10.1128/aac.35.5.910. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Piddock L. J., Wijnands W. J., Wise R. Quinolone/ureidopenicillin cross-resistance. Lancet. 1987 Oct 17;2(8564):907–907. doi: 10.1016/s0140-6736(87)91387-0. [DOI] [PubMed] [Google Scholar]
  10. Piddock L. J., Wise R. Mechanisms of resistance to quinolones and clinical perspectives. J Antimicrob Chemother. 1989 Apr;23(4):475–480. doi: 10.1093/jac/23.4.475. [DOI] [PubMed] [Google Scholar]
  11. Smith S. M., Eng R. H., Bais P., Fan-Havard P., Tecson-Tumang F. Epidemiology of ciprofloxacin resistance among patients with methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother. 1990 Oct;26(4):567–572. doi: 10.1093/jac/26.4.567. [DOI] [PubMed] [Google Scholar]
  12. Wolfson J. S., Hooper D. C. Fluoroquinolone antimicrobial agents. Clin Microbiol Rev. 1989 Oct;2(4):378–424. doi: 10.1128/cmr.2.4.378. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Yoshida S., Kojima T., Inoue M., Mitsuhashi S. Uptake of sparfloxacin and norfloxacin by clinical isolates of Staphylococcus aureus. Antimicrob Agents Chemother. 1991 Feb;35(2):368–370. doi: 10.1128/aac.35.2.368. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES